Arcus Biosciences, Inc.
ANTIBODIES TO TIGIT
Last updated:
Abstract:
The present disclosure provides antibodies that specifically bind to TIGIT. The antibodies have the capacity for substantial activation of T cells and natural killer cells by inhibiting binding of TIGIT to CD155. The antibodies can be used for treatment of cancer and infectious disease, among other applications.
Status:
Application
Type:
Utility
Filling date:
1 Jun 2021
Issue date:
3 Mar 2022